Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-06-04 Merger & Acquisition
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a communication filed pursuant to Rule 425 under the United States Securities Act of 1933, which is specifically mentioned in the text. Rule 425 filings are used for merger communications and related disclosures. The document discusses the appointment of a new CFO at AstraZeneca conditional upon the closing of AstraZeneca's acquisition of Alexion Pharmaceuticals, indicating it is related to merger activity. It also references the filing of a registration statement on Form F-4 and proxy statements related to the acquisition, reinforcing that this is a merger-related communication. The document is not a full annual report, earnings release, or other financial report but rather a regulatory filing related to a merger transaction. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive merger communication under Rule 425.
2021-06-04 English
Issuer Document
Capital/Financing Update Classification · 99% confidence The document is titled 'FINAL TERMS' and explicitly states, 'This document constitutes the Final Terms of the Notes described herein for the purposes of the UK Prospectus Regulation.' It details the terms of a specific debt issuance (EUR 800,000,000 0.375 per cent. Notes due 2029) under an existing Euro Medium Term Note Programme. This structure—Final Terms supplementing a Base Prospectus—is characteristic of securities offerings, specifically related to debt capital markets. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate category for documents detailing the final terms of a new bond issuance or financing activity, as opposed to a general regulatory filing (RNS) or a general report (10-K, IR).
2021-06-03 English
Regulatory Filings 2021
Regulatory Filings
2021-06-03 English
PUBLICATION OF FINAL TERMS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces the publication of Final Terms for a €800 million bond offering under an EMTN program. The document provides a link to the Final Terms and states that the Final Terms must be read in conjunction with a Base Prospectus. The document is relatively short (3184 characters) and primarily serves as an announcement of the availability of the Final Terms rather than containing the full financial or bond issuance details itself. This fits the pattern of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain the full report or detailed financial data. It is not a full Annual Report, Capital/Financing Update, or any other specific report type but rather a formal notification of the publication of bond issuance terms.
2021-06-02 English
Publication of Final Terms for €800m bond offering
Capital/Financing Update Classification · 98% confidence The document is titled 'FINAL TERMS' and explicitly states, 'This document constitutes the Final Terms of the Notes described herein for the purposes of the UK Prospectus Regulation.' It details the terms of a specific debt issuance: 'Issue of EUR 800,000,000 0.375 per cent. Notes due 2029 under the US$10,000,000,000 Euro Medium Term Note Programme.' This structure—Final Terms supplementing a Base Prospectus—is characteristic of securities offerings, specifically related to financing activities and capital structure. Among the provided codes, 'Capital/Financing Update (CAP)' is the most appropriate classification for documents detailing the final terms of a bond or note issuance.
2021-06-02 English
Publication of Final Terms
Capital/Financing Update Classification · 99% confidence The document is a short announcement (2901 chars) released via RNS (Regulatory News Service) on June 2, 2021. The title explicitly states 'Publication of Final Terms for €800m bond offering'. It provides a link to the 'Final Terms' document and notes that the information is provided by RNS, which acts as a Primary Information Provider. According to Rule 2, when a document is short and announces the publication of another document (like Final Terms for a bond issue), it should be classified as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this is a specific announcement about the publication of financing terms, RPA is a strong candidate, but given the context of RNS distribution and the nature of the announcement (a regulatory filing update), RNS is also appropriate. However, the core action is announcing the availability of a specific document (Final Terms), which aligns closely with the definition of RPA: 'Announcement regarding the timing, release, or publication of company reports'. Since 'Final Terms' are a type of regulatory disclosure, and the document itself is just the announcement wrapper, RPA is the most precise fit among the options for announcing a specific document's availability. If RPA were not available, RNS would be the fallback. Given the options, RPA fits best as it announces the publication of the Final Terms.
2021-06-02 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.